Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.

NCT01972763 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Recalcitrant Wet Age-related Macular Degeneration

Interventions

DRUG: Ranibizumab

Sponsor

Northern California Retina Vitreous Associates

Collaborators

[object Object]